Cargando…
Quantitative Systems Pharmacology for Neuroscience Drug Discovery and Development: Current Status, Opportunities, and Challenges
The substantial progress made in the basic sciences of the brain has yet to be adequately translated to successful clinical therapeutics to treat central nervous system (CNS) diseases. Possible explanations include the lack of quantitative and validated biomarkers, the subjective nature of many clin...
Autores principales: | Geerts, Hugo, Wikswo, John, van der Graaf, Piet H., Bai, Jane P.F., Gaiteri, Chris, Bennett, David, Swalley, Susanne E., Schuck, Edgar, Kaddurah‐Daouk, Rima, Tsaioun, Katya, Pelleymounter, Mary |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966183/ https://www.ncbi.nlm.nih.gov/pubmed/31674729 http://dx.doi.org/10.1002/psp4.12478 |
Ejemplares similares
-
Applications of Quantitative Systems Pharmacology in Model‐Informed Drug Discovery: Perspective on Impact and Opportunities
por: Bradshaw, Erica L., et al.
Publicado: (2019) -
Best Practices to Maximize the Use and Reuse of Quantitative and Systems Pharmacology Models: Recommendations From the United Kingdom Quantitative and Systems Pharmacology Network
por: Cucurull‐Sanchez, Lourdes, et al.
Publicado: (2019) -
Hallmarks of neurodegenerative disease: A systems pharmacology perspective
por: Bloomingdale, Peter, et al.
Publicado: (2022) -
MID3: Mission Impossible or Model‐Informed Drug Discovery and Development? Point‐Counterpoint Discussions on Key Challenges
por: Krishnaswami, Sriram, et al.
Publicado: (2020) -
Establishing Telemedicine in an Academic Total Joint Arthroplasty Practice: Needs and Opportunities Highlighted by the COVID-19 Pandemic
por: Rao, Sandesh S., et al.
Publicado: (2020)